Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$98.82 USD

98.82
666,765

+1.62 (1.67%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Buy Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard growth and raised guidance.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.

Quest Diagnostics (DGX) Presents New Data on Disease Testing

by Zacks Equity Research

Quest Diagnostics (DGX) is dedicated to create cutting-edge laboratory tests to help assess patient risk for dementia and other degenerative diseases.

Here's Why You Should Invest in Neogen (NEOG) Stock Now

by Zacks Equity Research

Investors are upbeat about Neogen (NEOG) owing to strong performance across its Animal Safety and Food Safety segments.

Baxter's (BAX) New Launch to Support Complex Critical Care Needs

by Zacks Equity Research

Baxter's (BAX) Progressa+ bed for the ICU is expected to enhance workflow and reduce strain on nursing resources.

Thermo Fisher's (TMO) New Launch to Advance Cancer Therapies

by Zacks Equity Research

Thermo Fisher's (TMO) Gibco OncoPro Tumoroid Culture Medium Kit is intended to increase researchers' access to sophisticated cancer models.

OPKO Health's (OPK) NGENLA Approved by FDA for GHD Treatment

by Zacks Equity Research

The latest approval for OPKO Health's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.

Walgreens (WBA) to Advance Diabetes Care at FFL Conference

by Zacks Equity Research

Walgreens (WBA) will sponsor Children with Diabetes' FFL event to make a difference in the lives of the 122 million individuals afflicted by diabetes and pre-diabetes.

Shaun Pruitt headshot

2 Medical Stocks to Consider Buying in June

by Shaun Pruitt

With solid top and bottom-line growth on the horizon for HealthEquity (HQY) and iRadimed (IRMD), they are starting to look like viable investments for 2023 and beyond.

Three Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

McKesson's (MCK) Latest Launch to Give Access to OTC Products

by Zacks Equity Research

McKesson's (MCK) latest launch is expected to meet the evolving needs and growing demand for quality OTC private-label health and wellness products.

Three Reasons to Add Masimo (MASI) Stock to Your Portfolio

by Zacks Equity Research

Masimo's (MASI) solid product suite raises optimism about the stock.

Walgreens Boots' (WBA) Q3 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Walgreens Boots' (WBA) U.S. Healthcare business expands, owing to key contract wins, continued partnership growth and a strong focus on execution.

Walgreens (WBA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strategic executions on the United States and the international front is likely to drive Walgreens' (WBA) Q3 revenues.

Wall Street Analysts Predict a 34.21% Upside in HealthEquity (HQY): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 34.2% upside potential for HealthEquity (HQY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

3 Reasons to Add HealthEquity (HQY) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.

What's in Store for Patterson Companies (PDCO) in Q4 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect an improvement at the Animal Health segment.

How Much Upside is Left in HealthEquity (HQY)? Wall Street Analysts Think 26.59%

by Zacks Equity Research

The consensus price target hints at a 26.6% upside potential for HealthEquity (HQY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here's Why HealthEquity (HQY) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Industry Outlook Highlights Medpace, HealthEquity and Apollo Medical

by Zacks Equity Research

Medpace, HealthEquity and Apollo Medical are part of the Zacks Industry Outlook article.

Urmimala Biswas headshot

3 Medical Services Stocks to Buy Amid Improving Industry Trends

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and AMEH are set to gain the most. However, staffing shortages may disrupt the trend.

HealthEquity (HQY) Surpasses Q1 Earnings Estimates, FY24 View Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2024.

HealthEquity (HQY) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for HealthEquity (HQY) give a sense of how the business performed in the quarter ended April 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

HealthEquity (HQY) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of 21.95% and 1.91%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?